iFAST Diagnostics
PrivateLast Round
Early Funding
May 28, 2026
Total Funding Raised
$15.25M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
iFAST Diagnostics operates in Healthcare & Life Sciences and is based in the United Kingdom. Its latest recorded funding round was an Early Funding round in May 2026.
iFAST Diagnostics is a biotechnology company that has developed a rapid antimicrobial susceptibility testing (AST) system to provide results in under three hours.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment, Biotechnology
Business Model
B2B
Customer Profile
Hardware + Subscription, Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iFAST Diagnostics Comparables
Compare iFAST Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gradientech | 91% | |
| Vivid Dx | 90% | |
| Cytophenix | 87% |
For institutional investors. Book with your work email.
iFAST Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | May 28, 2026 | ||||
| Seed | Nov 5, 2024 | ||||
| Pre Seed | Feb 16, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
iFAST Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OKG Capital | Early Funding |
| QantX | Seed, Early Funding, Pre Seed |
| Cambridge Capital Group | Early Funding |
| Raw Ventures | Seed, Early Funding |
| UK Innovation & Science Seed Fund | Pre Seed, Seed |
| Kadmos Capital | Pre Seed, Seed |
| Meridian Health Ventures | Pre Seed, Seed, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 78% MoM, reaching 2.3K.
- Aug 18, 2026
Grew 69% QoQ, from 16 to 27 employees.
For institutional investors. Book with your work email.
iFAST Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about iFAST Diagnostics's valuation, stock price, and market status.
Is iFAST Diagnostics a public or private company?
iFAST Diagnostics is a private company.
What is the current stock price of iFAST Diagnostics?
iFAST Diagnostics is a private company, so its shares have no public market price. Caplight tracks iFAST Diagnostics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is iFAST Diagnostics worth (valuation)?
Valuation information for iFAST Diagnostics is not publicly available.
Can I buy iFAST Diagnostics stock?
iFAST Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was iFAST Diagnostics's last funding round?
iFAST Diagnostics's most recent funding round was Early Funding on May 28, 2026.
Who are the main investors in iFAST Diagnostics?
Key investors in iFAST Diagnostics include QantX, Meridian Health Ventures.
Will iFAST Diagnostics IPO soon?
No public IPO plans have been announced for iFAST Diagnostics.
How can I track iFAST Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades in iFAST Diagnostics's shares on secondary markets.